Unwanted road to anaemia in transthyretin familial amyloid polyneuropathy may continue irrespective of tafamidis treatment.

Abstract

Background This retrospective longitudinal study was performed to determine whether tafamidis treatment leads to improvements in commonly used blood data for transthyretin familial amyloid polyneuropathy (TTR-FAP). Methods Commonly used blood data (complete blood count [including a haemogram], total protein, albumin, blood urea nitrogen, creatinine, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, lactate dehydrogenase, γ-glutamyl transpeptidase, total bilirubin [T-Bil], creatine kinase, choline esterase, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, estimated glomerular filtration rate [eGFR], serum amyloid A protein, TTR, haemoglobin A1c, free triiodothyronine [FT3] and free thyroxine [FT4]) were investigated in 33 TTR-FAP patients. These values included longitudinal data at three time points: six months before or after tafamidis treatment and one year after tafamidis treatment. Longitudinal changes in each blood item were examined using a linear mixed model, adjusting for age at starting tafamidis, sex, TTR-FAP stage and value before tafamidis treatment. Results Our results show elevated TTR concentrations after tafamidis treatment. In contrast, haemoglobin, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, mean platelet volume, platelet distribution width, T-Bil, eGFR, FT3 and FT4, gradually decreased through a reference range. There were no characteristic observations in any other items. TTR binds to thyroid hormone; therefore, FT3 and FT4 decreased in inverse proportion to increased TTR concentrations. Conclusion Unfortunately, progression to anaemia may occur regardless of tafamidis treatment. Because anaemia is sometimes present in TTR-FAP, attention should be paid to longitudinal changes in commonly used blood data, irrespective of tafamidis treatment.

• Authors: Tokunori Ikeda, Teruaki Masuda, Mitsuharu Ueda, Taro Yamashita, Yohei Misumi, Satoru Shinriki, Yukio Ando
• Journal: Annals of clinical biochemistry (Ann Clin Biochem) Vol. 55 Issue 5 Pg. 571-575 (Sep 2018) ISSN: 1758-1001 [Electronic] England
• PMID: 29310464 (Publication Type: Journal Article)

Chemical References

• Benzoxazoles
• tafamidis

Topics

• Amyloid Neuropathies, Familial (complications, physiopathology)
• Anemia (complications, physiopathology)
• Benzoxazoles (pharmacology)
• Blood Chemical Analysis
• Disease Progression
• Female
• Humans
• Longitudinal Studies
• Male
• Middle Aged
• Retrospective Studies